NEW YORK (GenomeWeb) – Veritas Genetics today said that its myBRCA screening test for hereditary breast and ovarian cancer has received CE marking in Europe.  

As a result, the Boston-based firm plans to make the test available in a select group of 15 countries, it said, though it did not disclose which 15 countries. The saliva-based test identifies mutations in the BRCA1 and BRCA2 genes with 99.99 percent accuracy, according to Veritas, and results are compared with a database representing more than 500,000 patients and 8,000 known mutations. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The Jackson Laboratory has filed a complaint accusing Nanjing University of breeding and re-selling its mouse models, the Hartford Courant reports.

Oxford researchers are turning to virtual reality to visualize genes and regulatory elements, Phys.org says.

In Science this week: neutrophils rely on microRNA to protect against lung inflammation, and more.

China is moving forward with plans to sequence a million citizens, the Wall Street Journal reports.